HTL0018318
Sponsors
Nxera Pharma UK Limited, Heptares Therapeutics Ltd.
Conditions
Alzheimer's DiseaseBioavailability and PharmacokineticsDementia With Lewy BodiesPharmacokineticsSafety IssuesSchizophrenia
Alzheimer's disease
dementia & schizophrenia
Phase 1
Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules
CompletedNCT02958696
Start: 2016-10-31End: 2017-01-31Updated: 2017-02-03
Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects
CompletedNCT03198624
Start: 2017-05-16End: 2017-08-20Updated: 2017-09-07
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care
CompletedNCT03456349
Start: 2017-11-10End: 2018-07-16Updated: 2018-07-20